Targeting cytochrome P450 CYP1B1 with a therapeutic cancer vaccine

Abstract

The role that the immune system plays in limiting tumor formation and growth is becoming increasingly clear and passive immunotherapeutic approaches, such as the use of monoclonal antibodies, are now being successfully applied in clinical practice. Active immunization against tumors, however, has not yet been shown to have the same level of clinical efficacy. Two important reasons for this lack of efficacy have to do with the antigens being targeted, as well as the immunization approaches that have been tested. This review will highlight some of the requirements thought to be important for the successful development of an active immunization approach, with a focus on the ongoing development efforts for a novel agent targeting the cytochrome P450 family member, CYP1B1.

Keywords::

• cytochrome P450 1B1
• immunotherapy
• plasmid DNA
• poly(lactide-co-glycolide)
• tumor-associated antigen
• ZYC300

Financial & competing interests disclosure

Thomas Luby is a full-time employee of MGI Pharma. The author has no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.